Inclusion Criteria:

          -  Histologically or cytologically confirmed advanced or recurrent/metastatic solid
             tumors or B-cell lymphomas, that are considered non-amenable to surgery or other
             curative treatments or procedures (if applicable)

          -  Measureable disease per RECIST v1.1 or Lugano Criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Received prior standard therapy for advanced or recurrent/metastatic disease as
             applicable to tumor type

          -  Received a maximum of 4 prior systemic treatment regimens (inclusive of chemotherapy,
             immunotherapy, and targeted therapy regimens) for advanced or recurrent/metastatic
             disease

          -  Life expectancy of ≥12 weeks, as per investigator judgement

        Exclusion Criteria:

          -  The following B-cell neoplasms: Burkitt lymphoma, lymphoblastic leukemia/lymphoma,
             lymphoplasmacytic lymphoma, chronic lymphocytic leukemia

          -  Prior therapy containing an anti-PD-L1 agent or T-cell agonist

          -  Current serious illness or medical condition including, but not limited to
             uncontrolled active infection

          -  Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy
             (including prior immunotherapy) and/or complications from prior surgical intervention
             before starting MCLA-145

          -  Prior ≥ Grade 3 immune-mediated AEs with anti-PD-1 therapy

          -  History of any grade immune-mediated ocular AEs.

          -  Known hypersensitivity or severe reaction to any component of MCLA-145 or formulation
             components

          -  Participants who have active or inactive autoimmune disease or syndrome (eg,
             rheumatoid arthritis, moderate or severe psoriasis, multiple sclerosis, inflammatory
             bowel disease) that has required systemic treatment in the past 2 years or who are
             receiving systemic therapy for an autoimmune or inflammatory disease (ie, with use of
             disease modifying agents, corticosteroids, or immunosuppressive drugs)